Matthew Maxwell Donley

CIK: 0001636642

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (22.2%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (44.4%)

Compensation grants

Other (G, F, J, C, D, …)3 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AUPH

Aurinia Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

AUPH
Aurinia Pharmaceuticals Inc.
Mar 2, 2026
Tax Payment(F)
Direct
40.8K shares at avg. $14.21$579K
AUPH
Aurinia Pharmaceuticals Inc.
Feb 27, 2026
Award(A)
Direct
58.2K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Feb 20, 2026
Tax Payment(F)
Direct
32.9K shares at avg. $14.40$474K
AUPH
Aurinia Pharmaceuticals Inc.
Jan 2, 2026
Award(A)
Direct
54.2K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Jan 2, 2026
Tax Payment(F)
Direct
42.8K shares at avg. $15.95$682K
AUPH
Aurinia Pharmaceuticals Inc.
Mar 4, 2025
Sale(S)
Direct
59K shares at avg. $7.92$467K
AUPH
Aurinia Pharmaceuticals Inc.
Mar 3, 2025
Award(A)
Direct
135.6K shares-
AUPH
Aurinia Pharmaceuticals Inc.
Mar 3, 2025
Sale(S)
Direct
65.9K shares at avg. $8.00$527K
AUPH
Aurinia Pharmaceuticals Inc.
Feb 28, 2025
Award(A)
Direct
82.8K shares-

		Type	Shares	Price		Ownership
Mar 2, 2026	AUPH Aurinia Pharmaceuticals Inc.	Tax Payment(F)	40,761	$14.21	$579,214	Direct
Feb 27, 2026	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	58,160	-	$0	Direct
Feb 20, 2026	AUPH Aurinia Pharmaceuticals Inc.	Tax Payment(F)	32,901	$14.40	$473,774	Direct
Jan 2, 2026	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	54,166	-	$0	Direct
Jan 2, 2026	AUPH Aurinia Pharmaceuticals Inc.	Tax Payment(F)	42,787	$15.95	$682,453	Direct
Mar 4, 2025	AUPH Aurinia Pharmaceuticals Inc.	Sale(S)	58,991	$7.92	$467,209	Direct
Mar 3, 2025	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	135,567	-	-	Direct
Mar 3, 2025	AUPH Aurinia Pharmaceuticals Inc.	Sale(S)	65,902	$8.00	$527,216	Direct
Feb 28, 2025	AUPH Aurinia Pharmaceuticals Inc.	Award(A)	82,781	-	-	Direct

1-9 of 9 transactions

About Donley Matthew Maxwell

Donley Matthew Maxwell (SEC CIK 0001636642) files insider reports with the SEC as Chief Operating Officer of Aurinia Pharmaceuticals Inc. (AUPH).

Signal8 holds 4 ownership filings by Donley Matthew Maxwell, all Form 4s, filed between Mar 4, 2025 and Mar 3, 2026. Those filings report 9 transactions, from Feb 28, 2025 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Donley Matthew Maxwell's filings is in EDMONTON, A0.

Recent filings by Donley Matthew Maxwell

Mar 2, 2026: Tax withholding of AUPH shares (Form 4, code F).
Feb 27, 2026: Grant or award of AUPH shares (Form 4, code A).
Feb 20, 2026: Tax withholding of AUPH shares (Form 4, code F).
Jan 2, 2026: Grant or award of AUPH shares (Form 4, code A).
Jan 2, 2026: Tax withholding of AUPH shares (Form 4, code F).

Other insiders filing for Aurinia Pharmaceuticals Inc. (AUPH)

Robertson Stephen P., Chief Legal Officer
Johnson Craig A, Director
Goetz Kathleen, Director
Nova Tina Susan, Director
Bailey Jeffrey Allen, Director
TANG KEVIN, Chief Executive Officer

How to read Form 4 transaction codes